← Back to patent-cliff list
CC-10015
Tier C — Watch / tradeCC-10015
Celgene Corporation
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：TNFα
Indications (approved)：Multiple myeloma, Sarcoidosis, Systemic lupus erythematosus
Regional status
US
Phase II
2014-09-16
EU
Phase II
2016-10-14
China
-
Japan
Phase II
2016-10-14
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of CC-10015?
Approved indications include: Multiple myeloma, Sarcoidosis, Systemic lupus erythematosus.
When does the CC-10015 patent expire?
No public expiry year is available for CC-10015 yet; this page updates once verified.
How do I get a quote for CC-10015 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-12